

REVIEW ARTICLE OPEN



A cell cycle centric view of tumour dormancy

William A. Weston¹ and Alexis R. Barr^{1,2}

© The Author(s) 2023

Tumour dormancy and recurrent metastatic cancer remain the greatest clinical challenge for cancer patients. Dormant tumour cells can evade treatment and detection, while retaining proliferative potential, often for years, before relapsing to tumour outgrowth. Cellular quiescence is one mechanism that promotes and maintains tumour dormancy due to its central role in reducing proliferation, elevating cyto-protective mechanisms, and retaining proliferative potential. Quiescence/proliferation decisions are dictated by intrinsic and extrinsic signals, which regulate the activity of cyclin-dependent kinases (CDKs) to modulate cell cycle gene expression. By clarifying the pathways regulating CDK activity and the signals which activate them, we can better understand how cancer cells enter, maintain, and escape from quiescence throughout the progression of dormancy and metastatic disease. Here we review how CDK activity is regulated to modulate cellular quiescence in the context of tumour dormancy and highlight the therapeutic challenges and opportunities it presents.

British Journal of Cancer (2023) 129:1535–1545; <https://doi.org/10.1038/s41416-023-02401-z>

INTRODUCTION

Disseminated tumour cells (DTCs) present a significant clinical challenge for cancer patients due to their ability to lay dormant for prolonged periods and metastasise to secondary sites to form more aggressive tumours [1]. Despite extensive improvements to cancer treatment, metastatic relapse remains common, with recurrence occurring in, for example, 85% of ovarian cancer patients, 30% of breast, 40% of prostate cancer, and 100% of glioblastoma patients [2–6]. Tumour dormancy describes how low- or non-proliferating DTCs evade treatment or immune clearance and survive below detectable levels, then initiate tumorigenesis at metastatic sites, sometimes years later [7]. Several mechanisms of dormancy have been proposed and can be grouped into extrinsic mechanisms, such as immune suppression or restricted blood supply, or intrinsic mechanisms, including ultra-slow cell cycling, balanced proliferation and apoptosis, or a prolonged state of quiescence [7–9]. Due to the heterogenous and dynamic nature of cancer progression, all these mechanisms are likely to contribute in some way to tumour dormancy. This review will focus on the specific mechanisms of cellular quiescence and how this may be involved more broadly in all forms of tumour dormancy.

In mammalian cells, quiescence is defined as a reversible state of cell cycle arrest in the G₀/G₁ phase of the cell cycle. There is significant heterogeneity among quiescent cells depending on the induction signal and cellular context but all share the common feature of retaining proliferative potential [10, 11]. The terms quiescence and dormancy, and even senescence, are often used interchangeably in the literature, which can cause confusion. Here, we use quiescence in the strictest sense - to refer to a reversible G₀/G₁ cell cycle arrest state. Dormancy is used here to describe the clinical phenotypes, and quiescence is only one aspect of this, as described above. The reversibility of cell cycle arrest and the

reduced proliferative rate of quiescence underpins the therapy evading and tumour initiating properties of dormant tumour cells. Many attribute tumour dormancy to quiescent cancer stem cells (CSCs), however, due to the ambiguity in defining CSCs, we will consider all quiescent cancer cells to be relevant in this review [12]. Targeting quiescent tumour cells could offer a therapeutic solution to tumour dormancy, either by (i) improving fractional killing of early treatments, (ii) permanently repressing their re-entry into the cell cycle, for example by driving them into senescence, or (iii) targeted killing. To better understand the role of quiescence in tumour dormancy, it will be important to fully clarify how tumour cells enter, maintain, and exit quiescence. Importantly, quiescence is distinct from senescence which describes a permanent exit from the cell cycle [13], making it unlikely for true senescent cells to reawaken and form recurrent tumours. There are reports of reversible senescence, where cells that display markers of senescence are able to resume proliferation. This is a heated debate and we refer interested readers to an excellent review on this [14]. However, we favour the view that true senescence is an irreversible state of cell cycle arrest and that ‘reversible senescence’ represents cells not fully committed to senescence, which arises due to a paucity of markers available to truly distinguish quiescent from senescent cells and a difficulty in tracking individual cell fates over very long periods of time.

The cellular decision to proliferate or enter quiescence must be tightly regulated for healthy development and tissue homeostasis, something which is achieved through control of the cell cycle. Progression into and through the cell cycle is driven by cyclin-dependent kinases (CDKs) and their corresponding cyclins [15]. Ultimately, all quiescent or proliferative signals converge on common cell cycle regulators to modulate the activity of CDKs (Fig. 1a). If CDK activity reaches the required threshold, cells will enter the cell cycle and proliferate. If not, cells will remain in

¹MRC London Institute of Medical Sciences, Du Cane Road, London W12 0NN, UK. ²Institute of Clinical Sciences, Imperial College London, Du Cane Rd, London W12 0NN, UK. email: abarr@ic.ac.uk




Fig. 1 The effect of CDK regulators and the relevant signalling pathways which impinge on them. a CDK regulation and the subsequent effect on Rb repression of cell cycle gene expression: CDK activity is directly regulated by various activating Cyclins, Cdc25 phosphatases, and CDK activating kinase (CAK), or by repressive INK4 and Cip/Kip CDK inhibitors (CKIs) [21, 22], and Myt1 and Wee1 kinases [20]. Active Cyclin-CDK complexes promote expression of cell cycle master transcription factor E2F through hyperphosphorylation of retinoblastoma protein (Rb) [20, 27, 165]. **b** Multiple signalling pathways converge on CDK activity to determine proliferation/quiescence decisions. The proliferative and quiescent signalling pathways shown here modulate CDK activity through activating Cyclins or repressive CKIs, (outlined in (a)). Though the pathways here are simplified and not exhaustive of all involved, they depict those most relevant to this review and to CDK control. The ERK/p38 signalling ratio is highlighted as it is a key determinant of quiescence [30, 154, 166]. Both extracellular signal regulated kinase (ERK) and p38 are MAPK family proteins which, when activated by MAPK phosphorylation cascades, will translocate into the nucleus to regulate cellular processes and modify gene expression [167, 168]. ERK1/2 transmits growth and mitogenic signals from RAS/RAF/MEK phosphorylation cascades and stabilisation of growth factor response transcription factor families FOS, JUN and MYC which then drive cell cycle gene expression, including Cyclins^{18,26–28}. Conversely, extracellular stress and inflammatory cytokines trigger phosphorylation cascades via MKK3/6 to activate p38, which reduces proliferation and promotes survival by increasing the expression of CKIs [167]. The TGF β and BMP pathway is a large pleiotropic signalling network that plays a key role in quiescence. Here we show only the relevant and simplified aspects of canonical and non-canonical pathways. Canonical TGF β signalling occurs when ligand-receptor binding causes phosphorylation of Smad proteins which translocate into the nucleus to join co-activator FoxO proteins. This active complex couples with transcription factors, such as p53, to increase expression of CKIs p15, p21 and p27. Non-canonical TGF β signalling describes when ligand-receptor binding stimulates MAPK cascades which regulate transcription via p38 mechanisms to modulate CDK activity [49, 50].

quiescence. In this way, cells can integrate intrinsic signals, such as cell size and stress, including replication stress or metabolic stress, with extrinsic cues, including ECM composition, nutrient availability, or growth factors, to ensure proliferation only occurs when required. Unsurprisingly, dysregulation of upstream pathways, or mutations in the central control mechanisms of the cell cycle are heavily associated with cancer and other pathologies [16]. Cellular quiescence requires reduced Cyclin-CDK activity, most commonly by either by upregulating CDK inhibitors (CKIs), or by degrading or downregulating cyclins (Fig. 1a).

In this review, we outline the key molecular mechanisms that converge on and impact CDK activity and, as such, regulate cellular quiescence during tumour dormancy. We provide examples of how cellular and acellular factors can impinge on these mechanisms to allow cells to induce, maintain, and exit quiescence. The models used to study tumour dormancy are largely based in vitro in cell lines and in vivo in mouse models, where cancer cells can be injected into mice and their ability to colonise and proliferate at metastatic sites is used as a measure of how dormant they are. These models both have their limitations in modelling human disease where tumours can remain dormant for decades, far beyond the available time to track cells in vitro or the maximum lifespan of 2.5 years for a mouse. However, important insights have been made in these systems and in our review, we discuss the experimental systems used and include information where these have been linked to human disease.

CONTROLLING QUIESCENCE/PROLIFERATION DECISIONS THROUGH CDK ACTIVITY

The cellular decision between quiescence or proliferation is thought to be made at the restriction point (RP), a time in the G1 phase of the cell cycle after which cells no longer require growth factor stimulation to proliferate [17, 18]. Growth factor stimulation in quiescence increases CyclinD expression (Fig. 1b), increasing CyclinD-CDK4/6 activity over a critical threshold. CyclinD-CDK4/6 phosphorylates the transcriptional repressor retinoblastoma protein (Rb) causing partial release of its inhibition of the transcription factor family E2F [19]. E2F transcription factors promote the expression of many proliferative genes including CyclinE, increasing CyclinE-CDK2 activity that further phosphorylates Rb. This creates a positive feedback loop through Rb hyperphosphorylation, allowing full E2F activation and ‘commitment’ to proliferation [19, 20]. Expression of CKIs of the INK4 family (p15^{INK4B}, p16^{INK4A}, p18^{INK4C} and p19^{INK4D}) that specifically inhibit CDK4 and CDK6 [21], or of the Cip/Kip family (p21^{Cip1}, p27^{Kip1} and p57^{Kip2}) capable of inhibiting all Cyclin-CDK complexes [20, 22], increase the threshold of CDK activity required to leave quiescence. One key regulator that can drive increased CKI levels is p38 kinase (Fig. 1b). p38 can also directly inhibit E2F transcriptional activity by phosphorylating the N-terminal region of Rb to make it unresponsive to Cyclin-CDK activity [23–25].

The precise timing and mechanisms underpinning passing the RP are a hot topic of current investigation [26], and above we

provide the 'canonical' view. There is also heterogeneity regarding a cell's 'depth' of quiescence, a term which will be used to describe a cell's distance from the critical threshold for CDK activity, or the RP. Experimentally, quiescence depth has been demonstrated by keeping cells in quiescence (e.g., by serum starvation) for different periods of time and then stimulating them to re-enter the cell cycle. Quiescent cells that have been out of the cell cycle for longer required more time or an increased stimulus (e.g., a higher concentration of growth factors) to re-enter the cell cycle [27].

In tumour dormancy, multiple growth factors and signals from the metastatic niche will contribute to proliferation/quiescence decisions. All these inputs are transduced and integrated through a few key signalling pathways that ultimately impact CDK regulators and CDK activity (Fig. 1b) [28]. We look at how these inputs decrease CDK activity such that cells either enter or maintain quiescence, which contributes to how tumour dormancy is established and maintained, and how CDKs can be reactivated, which can drive tumour relapse.

INDUCING DORMANCY: QUIESCENCE AND THE 'PRO-DORMANCY' NICHE

Though previously considered to be a late stage in cancer progression, dissemination of tumour cells may occur early in tumorigenesis. The delay of detectable metastatic lesions is due to cellular dormancy induced by the non-permissive environment of metastatic sites [7]. DTCs that invade the blood or lymphatic system disseminate widely in suspension, and frequently lodge in unfamiliar tissues with alternative homeostatic mechanisms, which may favour quiescence over proliferation [9]. Mounting evidence points to the existence of various 'pro-dormancy niches' in which DTCs lay dormant for extended periods of time before escaping quiescence to form metastatic lesions. However, even before extravasation from circulation into a new metastatic site, DTCs can enter a dormant-like state due to their loss of cell adhesion and nutrient availability. Floating spheroids isolated from ovarian cancer patients were shown to be arrested in quiescence, with increased levels of the Rb-like protein p130, the CKI p27 and reduced CDK4/6 activity [29]. Loss of adhesion in these spheroids removes integrin-FAK/RAS/ERK signalling and initiates a stress response that causes inhibition of AKT/PI3K signalling (Fig. 1b). This subsequently pushed cells into a ERK^{low}/p38^{high} profile [29], something which reduces proliferation and contributes to a quiescent phenotype [7, 25, 30–32], often through a common effector MSK1 [33, 34]. Indeed, in vitro models using aggregates of squamous carcinoma cells grown in a nutrient-deprived suspension, have been shown to arrest via growth factor-independent epidermal growth factor receptor (EGFR)-Y1086 autophosphorylation, which leads to reduced AKT signalling (Fig. 1b) and reduced CyclinD [35]. Here we describe some of the key mechanisms and niches known to induce DTC quiescence.

Secreted factors

Once DTCs invade a tissue from the vasculature they are frequently met with non-orthotopic microenvironments which promote quiescence through cell-cell adhesions, secreted factors, and specific ECM interactions [7]. While these niches exist in the brain, lung and liver, it is perhaps best studied in the bone marrow^{71,72}, therefore, this review will mainly focus on examples from this niche. Haematopoietic stem cells (HSC) are maintained in the endosteal niche within the bone microenvironment (BM) by spindle-like osteoblasts through several key secreted signals which are hijacked by DTCs to induce their quiescence and cell survival. One example is secreted Wnt5a, which has been shown to induce quiescence in the prostate cancer cell line, PC-3, in vitro [36]. Wnt5a binding its receptor ROR2 promotes SIAH1 and Ebi1 to ubiquitinate B-catenin for degradation, inhibiting proliferative

canonical Wnt signalling [37–40] (Fig. 1b) and reducing the expression of MYC and CyclinD to induce quiescence [36–38, 40]. In vivo studies using mouse models of prostate cancer confirmed that addition of Wnt5a reduces tumour burden (prolonged dormancy), while Wnt5a knockdown leads to increased detectable metastatic foci in the bone, which appeared sooner than in wild-type mice [36, 41]. Further evidence shows that BM-derived Wnt5a is significantly reduced in aged mice, which may account for the late development of metastatic lesions [36, 42]. Moreover, high ROR2 expression correlates with improved bone metastasis-free survival in prostate cancer patients [36]. While best characterised in bone marrow, similar research has shown Wnt5a to reduce cell cycling of melanoma metastases in the lung microenvironment, accompanied by elevated p21 expression, and delayed metastatic outgrowth [43].

Similar evidence exists for secreted TGF β and BMP signalling contributing to cellular quiescence [44–46], acting through canonical [47, 48] and non-canonical [49, 50] pathways to modulate CDK activity (Fig. 1b). Studies have implicated osteoblast-derived BMP5/6/7 in the quiescence of Myeloma cell lines [51] while in vivo models of metastatic breast cancer showed that BMP secreted by lung stromal cells prolongs phenotypic dormancy [52]. A paper by Kobayashi [53] gave in vitro and in vivo evidence that BMP7 secretion in the bone was preventing the outgrowth of metastatic prostate cancer cells through upregulation of p38 and p21, which caused a reversible state of cell cycle arrest. Moreover, murine models of metastatic prostate cancer have shown osteoblast secreted TGF β 2 and GDF10 are key to promoting cellular quiescence and maintaining tumour dormancy in the bone [41]. Both TGF β 2 and GDF10 ligands bind TGF β 3R to increase nuclear translocation of (active) phospho-p38 [41, 54], which deepens quiescence in prostate cancer cells by promoting expression of the CKI p27 [55].

Cell-cell interactions

In addition to secreting key factors, osteoblasts hold HSCs in the niche through cell-cell interactions via N-Cadherin, bringing about increased Notch2 signalling [56, 57]. High Notch2 signalling has been shown to cause cell cycle arrest in small cell lung cancer (SCLC) cell lines by upregulating CKIs p21 and p27, and inhibitory phosphorylation of ERK1 and ERK2 (Fig. 1b) [58]. A paper by Capulli et al. [59] modelling metastatic breast cancer, showed that disseminated cells were high in N-Cadherin, allowing them to compete with HSCs to engraft in the endosteal niche, where they are then kept quiescent by Notch signalling. Moreover, silencing of Notch1 and Notch2 abrogated the dormancy phenotype in mice with increased metastatic foci in the liver and other organs suggesting increased proliferation and metastasis. The same study highlighted how breast cancer patients with Notch2^{high} cancers have improved prognosis pre-treatment as their primary tumours are less proliferative leading to smaller primary lesions, but worse than Notch^{low} patients after chemotherapy [59], potentially because of an increased number of quiescent DTCs meaning metastatic relapse is more common.

Similar research using both spontaneous and intracardial injection-based mouse models of metastatic breast cancer, showed how quiescent DTCs accumulate at the microvascular endothelium of lung, brain, and bone [60]. Using in vitro models of lung microvascular networks, Ghajar et al. [60] showed how Thrombospondin-1 (TSP1), expressed on mature endothelial cells, maintained DTC quiescence. TSP1 is a surface protein of mature endothelial cells but can also induce quiescence when secreted by BM-derived myeloid cells [61]. Quiescence is likely due to TSP1 binding CD47, which upregulates CKIs p21 and p27 expression, while simultaneously inhibiting CyclinD1 [62]. Though the exact mechanism through which this occurs remains unclear, TSP1 has also been shown to upregulate TGF β signalling to repress tumour growth in cells isolated from primary breast

tumours, suggesting a possible common role for TSP1 in various dormant cancers [63].

Cell-ECM interactions

A wealth of evidence exists showing how extracellular matrix (ECM) composition and structure can influence tumour progression, as well as contribute to the normal and cancer stem cell niche [64, 65]. Multiple *in vitro* studies have shown how an ECM substrate is able to slow cancer cell proliferation in comparison to plastic monolayer cultures [66, 67]. Components of the basement membrane, including Collagen 4, TSP1 and Laminin-1 are known to induce quiescence in oestrogen-receptor positive (ER+) breast cancer cells growing *in vivo* or in 3D models [60, 68, 69]. The basement membrane is a known player in stem cell pool maintenance, and though the exact pathways are not clear in cancer, it is likely to be a similar mechanism in DTC quiescence. ECM biomechanics are also thought to affect cancer cell behaviour and bring about quiescence. Hepatocellular carcinoma (HCC) cell lines proliferate rapidly when cultured on a 'stiff' matrix due to increased focal adhesions, leading to elevated FAK/ERK and PKB/Akt signalling (Fig. 1b). However, when moved to a 'soft' substrate, HCC cells become quiescent, exhibiting decreased levels of CyclinD and CyclinE [70]. Similar evidence exists for breast cancer cells proliferating in more 'stiff' ECM and remaining quiescent in softer ECM, mimicking brain metastasis [71]. Indeed, increased stiffness has been associated to more aggressive tumours in pancreatic, ovarian, bladder and glioblastoma tumours [72–75], indicating its support of proliferation rather than quiescence.

Though there are myriad signalling pathways which can bring about quiescence, these appear to be elevated in 'pro-dormancy niches' where DTCs are more likely to lodge, enter quiescence and survive for prolonged periods. Frequently, DTCs inhabit stem cell niches due to their adaptation to slow proliferating and protective mechanisms required for stem cell maintenance. Some evidence suggests DTCs specifically target these niches based on chemoattraction and cell-binding, however, there is also a strong selection pressure against more hostile environments.

MAINTAINING DORMANCY—AVOIDING PROLIFERATION AND DEATH

The extended latency of quiescent cancer cells requires sustained antiproliferative signals such as those outlined above. However, there is mounting evidence that DTCs can maintain and compound their quiescent state via DNA modifications, autocrine signals, and niche modifications. Here we describe examples for quiescence maintenance mechanisms which are co-opted by cancer cells to maintain proliferative potential as well as avoid apoptosis or senescence.

Transcriptional rewiring for quiescence

A key aspect to maintaining quiescence in healthy cells is a modified transcriptional programme which consolidates antiproliferative signals. Many anti-proliferative gene regulators, such as p53, SALL2 or MXI1, are dysregulated in cancer to allow tumour formation despite cell stress or serum starvation [76–80]. However, some regulatory transcription factors have now been shown to perpetuate tumour dormancy by promoting a quiescent gene expression profile. Overexpression of the Lymphocyte Kruppel-like factor (LKLf) is sufficient to induce and maintain quiescence in leukemic T-cells *in vitro* [81]. LKLf maintains quiescence through inhibition of MYC, while associated transcription factors, Tob and FOXO, consolidate this quiescence by promoting p27 and antagonising CyclinE expression [81]. Recent work from Nobre et al. [82] in a spontaneous mouse model of Her2+ breast cancer identified an upregulation of the transcription factor ZFP281 in early metastases isolated from the lung, which promoted a quiescent-like expression profile that prevented tumour

outgrowth. Typically expressed in mouse and human embryonic stem cells, ZFP281 induces epithelial-to-mesenchymal transition through upregulation of Snail and Zeb1 transcription factors, which has been previously shown to suppress CyclinD1 and D2 expression [83, 84].

Chromatin modifications can produce longer lasting changes in gene expression to maintain quiescence. Histone methylation and acetylation can be activating or repressing, depending on context, and will often modify a network of related genes. Dormant human epidermoid carcinoma Hep3 cells *in vitro* and in mouse xenograft models were shown to enter quiescence through upregulation of DNA methyltransferase DNMT1, leading to the repression of proliferative genes [85]. The histone methyltransferase SMYD5 has also been shown to be necessary for dormancy of lung metastases in mice injected with breast cancer cells [86]. The orphan nuclear receptor NR2F1, commonly mutated in cancers [87, 88], was shown to be epigenetically upregulated downstream of TGF β /p38 signalling (Fig. 1b) in murine models of dormancy [85], as well as in DTCs isolated from long-term prostate cancer patients [89, 90]. NR2F1 and retinoic acid receptor β (RAR β) increase expression of the pluripotency factor SOX9 via activating Histone H3K4me3 modifications, resulting in increased expression of CKIs p15, p16 and p27 [89]. However, p38/NR2F1-induced quiescent cells maintained a globally repressive chromatin state with a H3K9me3^{high} and H3K27me3^{high} profile, typical of long-lived quiescent cells. Additional evidence from osteosarcoma xenografts in mice has shown the transcriptional repressor Hairy and Enhancer of Split 1 (HES1) to be associated with tumour dormancy and a more repressive chromatin state [91]. Downstream of Notch and Hedgehog signalling, HES1 contributes to preventing tumour cell differentiation by recruiting repressive histone deacetylases (HDACs) to its target genes, leading to chromatin compaction [91, 92]. This promotes quiescence and maintenance of the dormancy phenotype by repressing pro-apoptotic gene expression, or differentiation markers such as Mash1 or NeuroD [91].

The reversible nature of quiescence is heavily reliant on transcriptional changes and chromatin modification. These transient changes allow cells to maintain a non-proliferative state with low CDK activity and deepen quiescence by consolidating CKI expression, while avoiding terminal differentiation, senescence, or apoptosis. However, a strong enough mitogenic signal could still overcome these mechanisms to increase CDK activity and surpass the critical threshold for proliferation. Therefore, DTCs will often supplement their transcriptional changes with local niche modifications that further deepen quiescence.

Niche modification for quiescence

Rather than merely surviving in existing pro-dormancy niches, DTCs can actively remodel their microenvironment to improve the survival of metastases. Typically, the deposition of ECM proteins has been associated with escape from quiescence at metastatic sites such as the perivascular niche [93]. However, there is now evidence for DTCs modifying their metastatic environment to promote quiescence. This is likely to be commonplace when we consider the variety of tissues which can support the same DTCs; brain, bone, liver, and lung all support breast cancer cells [94]. An *in vitro* study by Barney et al. [95] showed ER+ breast cancer cells maintained in a prolonged quiescent state deposit an organised fibrillar Fibronectin (Fn) matrix to promote cell survival and maintain quiescence. Serum starved breast cancer cells received sustained autocrine TGF β 2 signalling (Fig. 1b) which initiates matrix remodelling via integrin α 5 β 1 binding and downstream Rho kinase activity [96]. The subsequent sustained α v β 3 and α 5 β 1 integrin binding by Fn permits arrested cells to suppress apoptosis via expression of Bcl-2 [97]. Indeed, quiescent breast cancer cells were shown to re-enter the cell cycle following specific degradation of Fn, and conversely, serum stimulated recovery of quiescent cells lead to a similar degradation of the Fn ECM by secreted

matrix metalloproteases (MMPs) [95]. More recent findings have shown that quiescent HNSCC lines injected into mice will deposit a collagen-3 (COL3A) rich matrix which promotes further COL3A expression via the collagen receptor DDR1 and downstream STAT1 signalling [98]. The COL3A rich matrix prolonged dormancy/reduced tumour burden in DTCs [98], potentially via STAT1 induced proteasomal degradation of CyclinD/CDK4 complexes [99].

As well as manipulating the ECM, DTCs can use local autocrine signals which 'deepen' their quiescent state and promote survival. Autocrine DKK1 enforces a state of quiescence in lung and breast cancer cells by inhibiting Wnt3a to reduce proliferative Wnt signalling [100], as well as reducing expression of the NK cell receptor ULBCP, allowing quiescent cells to escape immune clearance by natural killer cells. DKK3 has a similar quiescence inducing effect on prostate cancer cells in the BM, though the exact mechanism remains unclear [101]. A comparable autocrine Wnt3a inhibition mechanism was also identified in prostate cancer cells, responsible for reduced metastatic foci in mice [36]. Autocrine IGF1 signalling has recently been identified as an essential survival mechanism for quiescent cancer cells derived from murine pancreatic tumours, allowing for growth and apoptosis resistance in spite of mutations in KRAS or MYC. Insulin-like growth factor-1 (IGF1) was upregulated in the same cells, leading to increased AKT activation and cell survival. AKT signalling increased the proportion of functionally inactive apoptotic proteins BIM and BAD, and increased expression of the apoptosis inhibitor XIAP. Indeed, inhibition of IGF1/AKT signalling alongside c-MYC or KRAS inhibition increased pancreatic cancer cell clearance and delayed tumour recurrence in these mice [102].

Frequently, quiescence-inducing signals also stimulate downstream stress response pathways to promote cell survival. p38 can induce quiescence through upregulation of various endoplasmic reticulum stress response pathways to maintain cell health [25]. Quiescent human epidermoid carcinoma cell models subjected to environmental stress and chemotherapeutic insult *in vitro* have been shown to upregulate BiP and Eukaryotic translation initiation factor 2-alpha kinase 3 (PERK) in a p38-dependent manner, leading to increased protein chaperone production and inhibition of the apoptotic protein Bax [103]. Concurrently, p38 upregulates the survival transcription factor ATF6a when in a state of quiescence in these same cells¹⁵. ATF6a is trafficked from the endoplasmic reticulum to the nucleus by MKK6/p38 where it promotes the expression of unfolded protein response (UPR) genes, as well as increasing Rheb activated mTOR signalling. While AKT activated mTOR typically drives proliferation (Fig. 1b), here Rheb/mTOR promotes cell survival mechanism that allow quiescent DTCs to withstand stressors from their metastatic niche and sustain a dormant phenotype [104, 105].

There is some debate as to whether quiescence is induced and maintained through constant signalling input, or with a switch-like mechanism of cell reprogramming. Though external signals often drive cells into quiescence, the critical threshold of CDK activity can be increased further by switch-like changes to the chromatin structure and the transcriptional profile. These switches often feedback through autocrine signals, anti-apoptotic and stress pathways, and niche modifications which will combine to reduce CDK activation and consolidate quiescence. In some cases, DTCs will receive conflicting signals which may neutralise or reduce the impact of one another on CDK activity. However, provided cells have not entered senescence, even those DTCs in the deepest quiescence can re-enter proliferation, so long as the threshold of CDK activity is reached.

TUMOUR RELAPSE—QUIESCENCE TO PROLIFERATION

The process by which DTCs exit quiescence and initiate metastatic tumours will, in part, involve a gradual cessation of the pro-

quiescence signals depicted previously^{36,108}. Moreover, cellular quiescence may also be broken by passive events such as random epigenetic drift or decay over time^{109–111}. Though oncogenic mutation is slowed to almost zero in quiescent DTCs, a longitudinal *in vitro* study by Magnani et al. [106] suggests stochastic awakening events are inevitable due to the inherent instability of quiescent cell chromatin, which will decay with age to allow reactivation of proliferative genes. However, quiescent cell awakening can also be triggered by microenvironmental changes occurring through inflammation, ageing, growth factor stimulation, ECM remodelling, or migration to new tissues. Here we discuss some examples of quiescent cell activating signals and describe how they act to increase CDK activity.

Vascular perfusion and growth factors

While angiogenic dormancy is distinct from cellular quiescence [107], vascular perfusion of a dormancy niche is a strong predictor for DTC awakening and metastatic outgrowth. Neo-vascular tips create highly proliferative environments, rich in growth-promoting factors, oxygen, and nutrients which can be hijacked by DTCs to exit quiescence. A surplus of growth factors supplied by the blood will most often activate MAPK/Ras/ERK pathways to induce proliferation (Fig. 1b). Though established tumours are capable of inducing angiogenesis as previously reviewed [108, 109], there is currently no evidence of quiescent cells doing the same to drive outgrowth. However, injury and tissue repair are likely to encourage angiogenesis and other forms of tissue remodelling which could activate quiescent DTCs. Ghajar et al. [60] showed the pro-dormancy protein TSP1 was downregulated in neovascular tips of mice compared to established blood vessels, while TGFβ1 was upregulated and, triggered proliferation of injected breast cancer cells. TGFβ1 stimulates stromal fibroblasts to deposit an ECM matrix rich in Periostin, Tenascin-C (TNC) and Fn which is optimal for proliferation [60]. TNC and Periostin are known to amplify proliferative Wnt signals, to increase downstream activity of MYC and CyclinD [30]. In addition, Fn co-assembly with TNC increases integrin signalling capacity, driving proliferation through FAK/ERK pathways (Fig. 1b) [110]. Fn substrates have also been shown to promote motility in metastatic prostate cancer cell lines *in vitro* [111–113], which could enable DTCs to migrate to proliferative tissues, something which is made more likely by the proximity to blood vessels.

Inflammation and stress

Chronic inflammation is closely linked with cancer development and metastasis [114], and has been connected to relapse in patients with breast, oral and endometrial cancer [30, 115–117]. Prolonged inflammation leads to accumulation of immune cell secreted inflammatory cytokines such as interferon-gamma (IFN-γ), interleukin-1/6 (IL1/IL6) and Tumour necrosis factor (TNF) which have all been associated with metastatic relapse in patient studies of various cancer types [118, 119]. However, *in vitro* and mouse studies have attributed a large part of this association to mechanisms involving immune-mediated dormancy [120, 121], which we will not discuss here. In the context of quiescence, IL6 has been shown to drive proliferation in breast cancer by activating JAK/STAT3 signalling, which increases expression of MYC, B-catenin and CyclinD (Fig. 1b) [122, 123]. This effect can be boosted by IFN-γ activation of JAK-STAT, MAPK and PI3K signalling, which can drive proliferation as shown in Fig. 1b [124]. Khazali et al. [125] cultured breast cancer cells in an *ex vivo* liver system, to show how hepatic stellate cells could secrete the inflammatory cytokine IL8 to reduce cancer cell quiescence under serum starved conditions. This suggested that inflammation of the liver could contribute to late emergence of metastases in the liver. Meanwhile, immune cell secreted IL1 and TNF are highly pleiotropic cytokines that can indirectly induce exit from quiescence through activation of angiogenic factors IL6, IL8 and




Fig. 2 Cellular and acellular factors effecting DTC quiescence and outgrowth. Metastatic tumour cells enter quiescence prior to or during dissemination in the blood or lymph and can extravasate into new tissues. New tissues present unfamiliar homeostatic mechanisms which can continue to suppress growth for a time. Reciprocal signalling between DTCs and their environment drive migration or niche remodelling to generate a pro-metastatic or pro-dormancy niche. These niches effect quiescence/proliferation decisions by influencing the activity of CDKs in the cell.

VEGF, or by modification of the ECM via expression of MMPs [126, 127]. As with angiogenesis, inflammation acts as a trigger for microenvironmental change and ECM remodelling which can drive proliferation as discussed previously.

Pro-metastatic ECM and stroma

Just as stromal and ECM composition can be engineered to promote quiescence; they can also enable cell cycle re-entry. Aging, scarring or fibrosis can trigger increased deposition of Collagen-1 in the lungs and breast, both of which lead to matrix stiffening and increased FAK/RAS/ERK signals that drive proliferation [128–130]. COL1 also binds the Discoidin domain receptor (DDR1) causing further JAK/STAT3 signalling capable of activating SOX2 and MYC expression to increase proliferation [95, 131]. Matrix stiffness was shown to activate quiescent hepatocellular carcinoma cells (HCCs) via increased TGFb1 signalling that drives CyclinD1/3 expression [70]. Fn-rich matrices have been shown to induce an ERK^{high}/p38^{low} signalling ratio leading to high CDK activity. In this case, tight Fn bundles inhibit the activation of p38, while urokinase plasminogen activator receptor (uPAR) binds the $\alpha 5 \beta 1$ -integrin and drives high ERK activation [93, 132]. In some instances, DTCs can manipulate their own niche for quiescence exit, such as breast cancer cells, which deposit TNC once

metastasised to the lung. TNC deposition and binding promotes Wnt pathway signalling, and subsequently increases CDK activity via expression of MYC and CyclinD [133]. Breast cancer cells have also been shown secrete MMP9, which encourages exit from quiescence via angiogenesis or migration to new proliferative environments [134]. Similar research has revealed neutrophil extracellular traps (NETs) which promote quiescent to proliferation transitions by secretion of MMP-9. MMP-9 mediates the cleavage of laminin-111 and reveals integrin $\alpha 3 \beta 1$ activating epitopes that lead to increased FAK/ERK signalling [135].

We previously touched on how the expression of Wnt5a, an activator of quiescence for breast and prostate cancer cells, declines with age and possibly contributes to relapse in older age [36, 136]. Fane et al. [137] have since confirmed Wnt5a as a driver of dormant melanoma metastases in the lung. Using a series of in vitro and in vivo experiments they highlight how age-induced reprogramming of stromal fibroblasts in the lung increased their expression of sFRP1 leading DTCs to break from quiescence. sFRP1 antagonises Wnt5a leading to a loss of the dormancy phenotype and promoting metastatic outgrowth in mouse models. The examples above neatly demonstrate how tissues can evolve over time to support metastatic outgrowth rather than dormancy.




Fig. 3 Schematic showing the three dormancy treatment methods with examples. Quiescent cancer cells can be tackled using suppressive, activating, or specific targeting drugs. These can be applied in combination with typically anti-proliferative cancer drugs to reduce the number of DTCs and repress cancer outgrowth.

DISCUSSION

Converging signals at the metastatic niche

Here, we have explored how DTC quiescence can be induced, maintained, and exited, through signals which ultimately converge on the activity of CDKs through common CDK regulators (Fig. 1). Figure 2 depicts how CDK activity evolves over time as cells disseminate, extravasate, migrate and remodel their environments to establish 'pro-dormancy' or 'pro-metastatic' niches. While this is an effective model of metastasis and tumour dormancy, it is an oversimplification to suggest microenvironments are exclusively proliferative or quiescent in nature. In reality, DTCs frequently integrate opposing signals from the same niche, which combine to modulate the threshold of CDK activity and thus determine if cells will proliferate or enter quiescence.

We have seen how the BM provides an effective 'pro-dormancy' niche through myriad secreted factors, cell-cell interactions, and ECM deposition [41, 42, 138]. However, the BM is also a site of regenerative proliferation and differentiation of bone and immune cells in response to infection or injury, and as a result is rich in growth factors such as VEGF, IGFs, FGFs and BMPs [139–142]. BM-derived fibroblasts can drive HSC proliferation by secreting FGF-2 and -4 leading to ERK and PI3K activation (Fig. 1b) [143]. Despite this, the numerous strong quiescent signals in this BM niche mean the net effect on DTCs remains suppressive. In other organs the net difference between opposing signals may be much smaller, meaning quiescence is more short-lived in these niches. These dynamic niches are also subject to change following reciprocal signalling with DTCs, predictable evolution with age, and stochastic changes brought about by inflammation, scarring and repair. We have seen how quiescence in the perivascular niche of the lungs, supported by secreted Wnt5a and BMP signalling [36, 52, 136], can be counteracted by Wnt5a inhibition from aging stromal cell secretion of sFRP1, or Collagen1 deposition following scarring or ageing [129, 130].

The plasticity and heterogeneity of metastatic cancers and their niches makes a thorough comparison of dormancy mechanisms challenging, though common pathways are emerging as the literature expands. By clarifying the interplay of quiescent and proliferative signals at each site we can better understand the events leading to dormancy and outgrowth, which could lead to novel therapeutic opportunities in the future.

Clinical opportunities for tumour dormancy

Since conventional therapies target highly proliferative cells, quiescent DTCs possess an elevated tolerance to most treatments, which can be enforced by elevated stress response pathways and repression of apoptotic pathways (as reviewed here [144, 145]). While there are currently very few drugs specifically targeting quiescent cells, as our understanding of cellular quiescence and tumour dormancy improves, an increasing number of drugs are being co-opted to tackle quiescent DTCs, with many more in pre-clinical development [146–148]. Though many types of drugs are emerging, their applications fall within three techniques for treating tumour dormancy: 'Suppression', 'Activation' or 'Targeting' (Fig. 3).

Suppression describes a method by which relapse is prevented either by consolidation of pro-quiescence signals and the quiescent niche, or by inhibition of activating proliferative signals (Fig. 3). Inhibiting proliferative signals in ER+ breast cancer with the ER antagonist Tamoxifen is an established primary treatment and is now given up to 10 years after diagnosis to reduce relapse and improve patient survival [149, 150]. A similar application has now been approved for the CDK4/6 inhibitor Palbociclib, which is applied to metastatic ER+, HER2- breast cancer to keep residual DTCs quiescent [151, 152]. A new pilot study (*NCT03572387*) is assessing the use of retinoic acid (RA) 5-AZA and ATRA in prostate cancer patients to prolong dormancy by inducing a quiescent expression signature through activation of NR2F1 [146]. Alongside pre-approved drugs, many pre-clinical targets have been identified as effective DTC suppressors. Direct inhibition of proliferative Wnt signals with Wnt5a or DKK1 [36, 100], or ERK signalling with U0126 [130], as well as repressing ERK activators uPAR and B1-integrin [93, 153], have been shown to prevent outgrowth in pre-clinical models. Alternatively, upregulation of pro-dormancy signals like p38 [31, 41, 55, 154], TGFb2 [55, 155] and BMP4/7 [86, 156] have all been shown to reduce DTC proliferation in cell and animal models. Suppression has been shown to be effective in some instances but carries challenges regarding prolonged treatment toxicity, high economic cost, and possible selection for therapy resistant relapses.

Activation aims to re-establish DTC susceptibility to standard anti-proliferative therapies, to reduce or eradicate the quiescent cell population through primary treatment (Fig. 3), typically by

inhibiting pro-dormancy factors. Evidence from Boyerinas et al. [138] showed how Cytarabine treatment of leukaemic mice could be supplemented by OPN neutralisation to reduce the number of DTCs in the BM niche. Results from these preclinical models found that no residual disease was detectable, and relapse was significantly reduced [138]. In similar studies inhibiting DYRK1A [157] with Harmine improved the efficacy of Imatinib in clearing gastrointestinal cancer in mice [158], while DYRK1B inhibition combined with Gemcitabine was shown to improve pancreatic cancer cell killing in vitro [159]. DYRK1 is a kinase involved in the assembly and activation of the cell cycle inhibiting DREAM (dimerization partner, RB-like, E2F and multi-vulval class B) complex [160, 161]. DYRK1 and the DREAM complex are known to contribute to ovarian cancer quiescence, with in vitro evidence showing DYRK1 inhibition causes cancerous ovarian spheroids to lose viability and cells to exit quiescence [162]. Though there is evidence that activation can improve fractional killing in the first instance, few activation methods have reached clinical trials as they carry significant risk to recently diagnosed patients. This is because activation may exacerbate malignant phenotypes and establish a more aggressive cancer in patients.

Targeting offers the lowest risk to patients by exploiting highly specific pathways to eliminate DTCs. Some promising examples have been identified in pre-clinical studies (Fig. 3), but for direct targeting of quiescent cells to be a feasible method, it will require huge progress in our understanding of different quiescent cell populations. The most likely solution will come from combinatorial treatment based on specific information regarding the cancer subtype and genetic profile. Clinical studies have begun to explore Palbociclib in combination with various other adjuvant therapies (NCT04841148) targeting autophagy and the programmed cell death checkpoint, to optimise DTC clearance. Indeed, the use of clinically approved HDAC inhibitors to open chromatin and reawaken quiescent cells is viable but is only most effective when used in conjunction with other chemotherapies [146, 163]. By shifting plastic cancer cells to more vulnerable states and eliminating their survival mechanisms, we can reduce residual disease during the first round of treatment [164].

Despite significant interest in recent years, our understanding of the role of cellular quiescence in tumour dormancy remains far from complete, particularly considering the heterogeneity of cancer types and their metastatic sites. Though good progress has been made in existing models, the lack of diversity in the models used for investigating tumour dormancy is likely limiting our understanding of these heterogeneous cells. As well as increasing diversity, effort must be made to create preclinical models that can better simulate the kinetics of residual disease, to view the role of metastasis, niche modification, and cell-cell interactions simultaneously.

REFERENCES

- Karrison TG, Ferguson DJ, Meier P. Dormancy of mammary carcinoma after mastectomy. *J Natl Cancer Inst.* 1999;91:80–5.
- Shepherd TG, Dick FA. Principles of dormancy evident in high-grade serous ovarian cancer. Vol. 17, Cell Division. BioMed Central Ltd; 2022.
- Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thürlimann B, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. *J Clin Oncol.* 2016;34:927–35.
- Kurbegovic S, Berg KD, Thomsen FB, Gruschy L, Iversen P, Brasso K, et al. The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy. *Scand J Urol.* 2017;51:450–6.
- Rapp M, Baernreuther J, Turowski B, Steiger HJ, Sabel M, Kamp MA. Recurrence pattern analysis of primary glioblastoma. *World Neurosurg.* 2017;103:733–40.
- Jiang H, Yu K, Li M, Cui Y, Ren X, Yang C, et al. Classification of progression patterns in glioblastoma: analysis of predictive factors and clinical implications. *Front Oncol.* 2020;10:590648.
- Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. *Nat Rev Cancer.* 2007;7:834–46.
- Teng MWL, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. *J Leukoc Biol.* 2008;84:988–93.
- Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. *Nat Rev Cancer.* 2014;14:611–22.
- Coller HA, Sang L, Roberts JM. A new description of cellular quiescence. *PLoS Biol.* 2006;4:0329–49.
- Sang L, Coller HA, Roberts JM. Control of the reversibility of cellular quiescence by the transcriptional repressor HES1. *Science.* 2008;321:1095–100.
- Hen O, Barkan D. Dormant disseminated tumor cells and cancer stem/progenitor-like cells: similarities and opportunities. Vol. 60. *Seminars in cancer biology.* Academic Press; 2020. p. 157–65.
- Terzi MY, Izmirli M, Gogebakan B. The cell fate: senescence or quiescence. *Mol Biol Rep.* 2016;43:1213–20.
- Lee S, Schmitt CA. The dynamic nature of senescence in cancer. *Nat Cell Biol.* 2019;21:94–101.
- Morgan DO. CYCLIN-DEPENDENT KINASES: Engines, Clocks, and Microprocessors [Internet]. Vol. 13, *Annu. Rev. Cell Dev. Biol.* 1997. www.annualreviews.org.
- Foster I. Cancer: a cell cycle defect. *Radiography.* 2008;14:144–9.
- Yen A, Pardee AB. Exponential 3T3 cells escape in mid-G1 from their high serum requirement. *Exp Cell Res.* 1978;116:103–13.
- Pardee AB. A Restriction Point for Control of Normal Animal Cell Proliferation (growth control/cell survival/cancer). *Proc Natl Acad Sci USA.* 1974;71:1286–90.
- Zetterberg A, Larsson O, Wiman G. What is the restriction point? *Curr Opin Cell Biol.* 1995;7:835–42.
- Pennycook BR, Barr AR. Restriction point regulation at the crossroads between quiescence and cell proliferation. *FEBS Lett.* 2020;594:2046–60.
- Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. *Biochim Biophys Acta.* 2002;1602:73–87.
- Yoon MK, Mitrea DM, Ou L, Kriwacki RW. Cell cycle regulation by the intrinsically disordered proteins p21 and p27. *Biochem Soc Trans.* 2012;40:981–8.
- Gubern A, Joaquin M, Marqués M, Maseres P, Garcia-Garcia J, Amat R, et al. The N-terminal phosphorylation of RB by p38 bypasses its inactivation by CDKs and prevents proliferation in cancer cells. *Mol Cell.* 2016;64:25–36.
- Joaquin M, de Nadal E, Posas F, An RB. insensitive to CDK regulation. *Mol Cell Oncol.* 2017;4:e1268242.
- Martínez-Limón A, Joaquin M, Caballero M, Posas F, de Nadal E. The p38 pathway: from biology to cancer therapy. *Int J Mol Sci.* 2020;21:1913.
- Brooks RF. Commentary: locating the restriction point. *Cell Div.* 2023;18:2.
- Kwon JS, Everetts NJ, Wang X, Wang W, Della Croce K, Xing J, et al. Controlling depth of cellular quiescence by an Rb-E2F network switch. *Cell Rep.* 2017;20:3223–35.
- Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. *Int J Mol Sci.* 2020;21:1960.
- Correa RJM, Peart T, Valdes YR, DiMattia GE, Shepherd TG. Modulation of AKT activity is associated with reversible dormancy in ascites-derived epithelial ovarian cancer spheroids. *Carcinogenesis.* 2012;33:49–58.
- Park SY, Nam JS. The force awakens: metastatic dormant cancer cells. *Exp Mol Med.* 2020;52:569–81.
- Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and p38 α / β signaling in tumor cell quiescence: opportunities to control dormant residual disease. *Clin Cancer Res.* 2011;17:5850–7.
- Villanueva J, Yung Y, Walker JL, Assoian RK. ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. *Mol Biol Cell.* 2007;18:1457–63.
- Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, et al. MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. *Nat Cell Biol.* 2018;20:211–21.
- Vicent GP, Ballaré C, Nacht AS, Clausell J, Subtil-Rodríguez A, Quiles I, et al. Induction of progesterone target genes requires activation of Erk and Msk kinases and phosphorylation of histone H3. *Mol Cell.* 2006;24:367–81.
- Humtsoe JO, Kramer RH. Differential epidermal growth factor receptor signaling regulates anchorage-independent growth by modulation of the PI3K/AKT pathway. *Oncogene.* 2010;29:1214–26.
- Ren D, Dai Y, Yang Q, Zhang X, Guo W, Ye L, et al. Wnt5a induces and maintains prostate cancer cells dormancy in bone. *J Exp Med.* 2019;216:428–49.
- He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-*MYC* as a target of the APC pathway. *Science.* 1998;281:1509–12.
- Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, et al. The cyclin D1 gene is a target of the β -catenin/LEF-1 pathway. *Proc Natl Acad Sci.* 1999;96:5522–7.
- Yang K, Wang X, Zhang H, Wang Z, Nan G, Li Y, et al. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: Implications in targeted cancer therapies. *Lab Invest.* 2016;96:116–36.

40. Tetsu O, McCormick F. β -Catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature*. 1999;398:422–6.
41. Yu-Lee LY, Yu G, Lee YC, Lin SC, Pan J, Pan T, et al. Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGF β RIII–p38MAPK–pS249/ T252RB pathway. *Cancer Res*. 2018;78:2911–24.
42. Rauner M, Sipos W, Pietschmann P. Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation. *Age (Omaha)*. 2008;30:273–82.
43. Fane ME, Chhabra Y, Alicea GM, Maranto DA, Douglass SM, Webster MR, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. *Nature*. 2022;606:396–405.
44. Prunier C, Baker D, ten Dijke P, Ritsma L. TGF- β family signaling pathways in cellular dormancy. *Trends Cancer*. 2019;5:66–78.
45. Seoane J, Gomis RR. TGF- β family signaling in tumor suppression and cancer progression. *Cold Spring Harb Perspect Biol*. 2017;9:a022277.
46. Scandura JM, Bocconi P, Massagué J, Nimer SD. Transforming growth factor β -induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. *Proc Natl Acad Sci*. 2004;101:15231–6.
47. Seoane J, Pouppnot C, Staller P, Schader M, Eilers M, Massagué J. TGF β influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. *Nat Cell Biol*. 2001;3:400–8.
48. Seoane J, Le HV, Shen L, Anderson SA, Massagué J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. *Cell*. 2004;117:211–23.
49. Tzavlaki K, Moustakas A. TGF- β signaling. *Biomolecules*. 2020;10:487.
50. Wang RN, Green J, Wang Z, Deng Y, Qiao M, Peabody M, et al. Bone Morphogenetic Protein (BMP) signaling in development and human diseases. *Genes Dis*. 2014;1:87–105.
51. Baade RoT, Utne Holt R, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. *Oncogene*. 2004;23:3024–32.
52. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. *Cell*. 2012;150:764–79.
53. Kobayashi A, Okuda H, Xing F, Pandey PR, Watabe M, Hirota S, et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. *J Exp Med*. 2011;208:2641–55.
54. Gubern A, Joaquin M, Marqués M, Maseres P, Garcia-Garcia J, Amat R, et al. The N-terminal phosphorylation of RB by p38 bypasses its inactivation by CDKs and prevents proliferation in cancer cells. *Mol Cell*. 2016;64:25–36.
55. Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, et al. TGF- β 2 dictates disseminated tumour cell fate in target organs through TGF- β -RIII and p38 α / β signalling. *Nat Cell Biol*. 2013;15:1351–61.
56. Weber JM, Calvi LM. Notch signaling and the bone marrow hematopoietic stem cell niche. *Bone*. 2010;46:281–5.
57. Zhao M, Tao F, Venkatraman A, Li Z, Smith SE, Unruh J, et al. N-cadherin-expressing bone and marrow stromal progenitor cells maintain reserve hematopoietic stem cells. *Cell Rep*. 2019;26:652–69.e6.
58. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells 1. *Cancer Res*. 2001;61:3200–5.
59. Capulli M, Hristova D, Valbret Z, Carys K, Arjan R, Maurizi A, et al. Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. *Br J Cancer*. 2019;121:157–71.
60. Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumour dormancy. *Nat Cell Biol*. 2013;15:807–17.
61. Catena R, Bhattacharya N, El Rayes T, Wang S, Choi H, Gao D, et al. Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. *Cancer Discov*. 2013;3:578–89.
62. Gao Q, Chen K, Gao L, Zheng Y, Yang YG. Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells. *Cell Death Dis*. 2016;7:e2368.
63. Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. *Breast Cancer Res Treat*. 2009;114:85–96.
64. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144:646–74.
65. Nallanthighal S, Heiserman JP, Cheon DJ. The role of the extracellular matrix in cancer stemness. *Front Cell Dev Biol*. 2019;7:86.
66. Keeratichamroen S, Lirdprapamongkol K, Svasti J. Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells. *Oncol Rep*. 2018;39:1765–74.
67. Pogány G, Timár F, Oláh J, Harisi R, Polony G, Paku S, et al. Role of the basement membrane in tumor cell dormancy and cytotoxic resistance. *Oncology*. 2001;60:274–81.
68. Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, et al. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. *Nat Cell Biol*. 2019;21:238–50.
69. Ovadia EM, Pradhan L, Sawicki LA, Cowart JE, Huber RE, Polson SW, et al. Understanding ER+ breast cancer dormancy using bioinspired synthetic matrices for long-term 3D culture and insights into late recurrence. *Adv Biosyst*. 2020;4:2000119.
70. Schrader J, Gordon-Walker TT, Aucott RL, van Deemter M, Quaas A, Walsh S, et al. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. *Hepatology*. 2011;53:1192–205.
71. Kondapaneni RV, Rao SS. Matrix stiffness and cluster size collectively regulate dormancy: versus proliferation in brain metastatic breast cancer cell clusters. *Biomater Sci*. 2020;8:6637–46.
72. Itoh Y, Takehara Y, Kawase T, Terashima K, Ohkawa Y, Hirose Y, et al. Feasibility of magnetic resonance elastography for the pancreas at 3T. *J Magn Reson Imaging*. 2016;43:384–90.
73. Miroshnikova YA, Mouw JK, Barnes JM, Pickup MW, Lakins JN, Kim Y, et al. Tissue mechanics promote IDH1-dependent HIF1 α -tenascin C feedback to regulate glioblastoma aggression. *Nat Cell Biol*. 2007;3:91. www.plosgenetics.org.
74. Mieulet V, Garnier C, Kieffer Y, Guilbert T, Nemati F, Marangoni E, et al. Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer. *Sci Rep*. 2021;11:4219.
75. Ghasemi H, Mousavibahar SH, Hashemnia M, Karimi J, Khodadadi I, Mirzaei F, et al. Tissue stiffness contributes to YAP activation in bladder cancer patients undergoing transurethral resection. *Ann N Y Acad Sci*. 2020;1473:48–61.
76. Liu H, Adler AS, Segal E, Chang HY. A transcriptional program mediating entry into cellular quiescence. *PLoS Genet*. 2007;3:91. www.plosgenetics.org.
77. Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E, et al. Activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. *Curr Biol*. 2006;16:1171–82.
78. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. *Cell Death Differ*. 2003;10:404–8.
79. Hankey W, Frankel WL, Groden J. Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. *Cancer Metastasis Rev*. 2018;37:159–72.
80. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV. Mutation of the MXI1 gene in prostate cancer. *Nat Genet*. 1995;9:249–55.
81. Yusuf I, Fruman DA. Regulation of quiescence in lymphocytes. *Trends Immunol*. 2003;24:380–6.
82. Nobre AR, Dalla E, Yang J, Huang X, Wullkopf L, Risson E, et al. ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung. *Nat Cancer*. 2022;3:1165–80.
83. Mejlvang J, Krijavetska M, Vandewalle C, Chernova T, Sayan AE, Bex G, et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. *Mol Biol Cell*. 2007;18:4615–24.
84. Vega S, Morales AV, Ocaña OH, Valdés F, Fabregat I, Nieto MA. Snail blocks the cell cycle and confers resistance to cell death. *Genes Dev*. 2004;18:1131–43.
85. Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, et al. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. *Cancer Res*. 2009;69:5664–72.
86. Gao H, Chakraborty G, Lee-Lim AP, Mavrikis KJ, Wendel HG, Giancotti FG. Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation. *Proc Natl Acad Sci*. 2014;111:16532–7.
87. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. *Cancer Cell*. 2010;18:11–22.
88. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. *Cancer Cell*. 2006;9:121–32.
89. Sosa MS, Parikh F, Maia AG, Estrada Y, Bosch A, Bragado P, et al. NR2F1 controls tumour cell dormancy via SOX9- and RAR β -driven quiescence programmes. *Nat Commun*. 2015;6:6170.
90. Borgen E, Rypdal MC, Sosa MS, Renolen A, Schlichting E, Lønning PE, et al. NR2F1 stratifies dormant disseminated tumour cells in breast cancer patients. *Breast Cancer Res*. 2018;20:120.
91. Liu ZH, Dai XM, Du B. Hes1: a key role in stemness, metastasis and multidrug resistance. *Cancer Biol Ther*. 2015;16:353–9.
92. Sang L, Roberts JM, Collier HA. Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. *Trends Mol Med*. 2010;16:17–26.
93. Ghiso JAA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. *J Cell Biol*. 1999;147:89–104.
94. Di M, Julie S, Akhter T, Bravo-Cordero JJ. Remodeling the ecm: Implications for metastasis and tumor dormancy. *Cancers (Basel)*. 2021;13:4916.

95. Barney LE, Hall CL, Schwartz AD, Parks AN, Sparages C, Galarza S, et al. Tumor cell-organized fibronectin maintenance of a dormant breast cancer population. *Sci Adv.* 2020;6:eaaaz4157.
96. Barrios J, Wieder R. Dual FGF-2 and integrin $\alpha 5 \beta 1$ signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy. *Cancer Microenviron.* 2009;2:33.
97. Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. *Proc Natl Acad Sci.* 1995;92:6161–5.
98. Di Martino JS, Nobre AR, Mondal C, Taha I, Farias EF, Fertig EJ, et al. A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy. *Nat Cancer.* 2021;3:90–107.
99. Dimco G, Knight RA, Latchman DS, Stephanou A. STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest. *Cell Cycle.* 2010;9:4638–49.
100. Yu-Lee LY, Lee YC, Pan J, Lin SC, Pan T, Yu G, et al. Bone secreted factors induce cellular quiescence in prostate cancer cells. *Sci Rep.* 2019;9:18635.
101. Malladi S, MacAlinao DG, Jin X, He L, Basnet H, Zou Y, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. *Cell.* 2016;165:45–60.
102. Rajbhandari N, Lin WC, Wehde BL, Triplett AA, Wagner KU. Autocrine IGF1 signaling mediates pancreatic tumor cell dormancy in the absence of oncogenic drivers. *Cell Rep.* 2017;18:2243–55.
103. Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced up-regulation of BiP and activation of RNA-dependent protein Kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. *Cancer Res.* 2006;66:1702–11.
104. Schewe DM, Aguirre-Ghiso JA. ATF6-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo [Internet]. 2008. Available from: www.pnas.org/cgi/content/full/.
105. Hung CM, Garcia-Haro L, Sparks CA, Guertin DA. mTOR-dependent cell survival mechanisms. *Cold Spring Harb Perspect Biol.* 2012;4:a008771–a008771.
106. Rosano D, Sofyali E, Dhiman H, Ivanouiu D, Slaven I, Pil HS, et al. Unperturbed dormancy recording reveals stochastic awakening strategies in endocrine treated breast cancer cells. *BioRxiv.* 2021.
107. Endo H, Inoue M. Dormancy in cancer. *Cancer Sci.* 2019;110:474–80.
108. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. *Cell Mol Life Sci.* 2020;77:1745–70.
109. Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. *J Exp Clin Cancer Res.* 2020;39:204.
110. Park SY, Nam JS. The force awakens: metastatic dormant cancer cells. *Exp Mol Med.* 2020;52:569–81.
111. Rick JW, Chandra A, Dalle Ore C, Nguyen AT, Yagnik G, Aghi MK. Fibronectin in malignancy: cancer-specific alterations, protumoral effects, and therapeutic implications. *Semin Oncol.* 2019;46:284–90.
112. Zeng ZZ, Jia Y, Hahn NJ, Markwart SM, Rockwood KF, Livant DL. Role of focal adhesion kinase and phosphatidylinositol 3'-Kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells. *Cancer Res.* 2006;66:8091–9.
113. Barkan D, Kleinman H, Simmons JL, Asmussen H, Kamaraju AK, Hoenorhoff MJ, et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. *Cancer Res.* 2008;68:6241–50.
114. Coussens LM, Werb Z. Inflammation and cancer. *Nature.* 2002;420:860–7.
115. Bowers LW, Maximo IXF, Brenner AJ, Beeram M, Hursting SD, Price RS, et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin- α romatase interactions. *Cancer Res.* 2014;74:4446–57.
116. Okubo M, Kioi M, Nakashima H, Sugiura K, Mitsudo K, Aoki I, et al. M2-polarized macrophages contribute to neovascularogenesis, leading to relapse of oral cancer following radiation. *Sci Rep.* 2016;6:27548.
117. Machida H, De Zoysa MY, Takiuchi T, Hom MS, Tierney KE, Matsuo K. Significance of monocyte counts at recurrence on survival outcome of women with endometrial cancer. *Int J Gynecol Cancer.* 2017;27:302–10.
118. Duffy SA, Taylor JMG, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. *Cancer.* 2008;113:750–7.
119. Cole SW. Chronic inflammation and breast cancer recurrence. *J Clin Oncol.* 2009;27:3418–9.
120. Hallermalm K, Seki K, De Geer A, Motyka B, Bleackley RC, Jager MJ, et al. Modulation of the tumor cell phenotype by IFN- γ results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. *J Immunol.* 2008;180:3766–74.
121. Kmiecik M, Payne KK, Wang XY, Manjili MH. IFN- γ R α is a key determinant of CD8 $^{+}$ T cell-mediated tumor elimination or tumor escape and relapse in FVB mouse. *PLoS One.* 2013;8:e82544.
122. Manore SG, Doheny DL, Wong GL, Lo HW. IL-6/JAK/STAT3 signaling in breast cancer metastasis: biology and treatment. *Front Oncol.* 2022;12:866014.
123. Zhou Y, Chen JJ. STAT3 plays an important role in DNA replication by turning on WDH1. *Cell Biosci.* 2021;11:10.
124. Mojic M, Takeda K, Hayakawa Y. The dark side of IFN- γ : its role in promoting cancer immunoevasion. *Int J Mol Sci.* 2017;19:89.
125. Khazali AS, Clark AM, Wells A. Inflammatory cytokine IL-8/CXCL8 promotes tumour escape from hepatocyte-induced dormancy. *Br J Cancer.* 2018;118:566–76.
126. Gelfo V, Romaniello D, Mazzeschi M, Sgarzi M, Grilli G, Morselli A, et al. Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies. *Int J Mol Sci.* 2020;21:6009.
127. Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? *Acta Pharm Sin.* 2008;29:1275–88.
128. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. *Eur J Cancer.* 2010;46:1181–8.
129. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. *Nat Rev Cancer.* 2009;9:108–22.
130. Barkan D, El Touny LH, Michalowski AM, Smith JA, Chu I, Davis AS, et al. Metastatic growth from dormant cells induced by a Col-I-enriched fibrotic environment. *Cancer Res.* 2010;70:5706–16.
131. Gao H, Chakraborty G, Zhang Z, Akalay I, Gadiya M, Gao Y, et al. Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling. *Cell.* 2016;166:47–62.
132. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. Urokinase receptor and fibronectin regulate the ERK^{MAPK} to p38^{MAPK} activity ratios that determine carcinoma cell proliferation or dormancy in vivo. *Mol Biol Cell.* 2001;12:863–79.
133. Oskarsson T, Acharyya S, Zhang XHF, Vanharanta S, Tavazoie SF, Morris PG, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. *Nat Med.* 2011;17:867–74.
134. Mehner C, Hockla A, Miller E, Ran S, Radisky DC, Radisky ES. Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. *Oncotarget.* 2014;5:2736–49.
135. Albregues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. *Science.* 2018;361:eaa04227.
136. Jönsson M, Dejmeck J, Bendahl PO, Andersson T. Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. *Cancer Res.* 2002;62:409–16.
137. Fane ME, Chhabra Y, Alicea GM, Maranto DA, Douglass SM, Webster MR, et al. Stromal changes in the aged lung induce an emergence from melanoma dormancy. *Nature.* 2022;606:396–405.
138. Boyerinas B, Zafir M, Yesilkamal AE, Price TT, Hyjek EM, Sipkins DA. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. *Blood.* 2013;121:4821–31.
139. Soltan M, Smiler D, Choi JH. Bone marrow: orchestrated cells, cytokines, and growth factors for bone regeneration. *Implant Dent.* 2009;18:132–41.
140. Devescovi V, Leonardi E, Ciapetti G, Cenni E. Growth factors in bone repair. *Chir Organ Mov.* 2008;92:161–8.
141. Korf-Klingebiel M, Kempf T, Sauer T, Brinkmann E, Fischer P, Meyer GP, et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. *Eur Heart J.* 2008;29:2851–8.
142. Johnson CB, Zhang J, Lucas D. The role of the bone marrow microenvironment in the response to infection. *Front Immunol.* 2020;11:585402.
143. Choi SC, Kim SJ, Choi JH, Park CY, Shim WJ, Lim DS. Fibroblast growth factor-2 and -4 promote the proliferation of bone marrow mesenchymal stem cells by the activation of the PI3K-Akt and ERK1/2 signaling pathways. *Stem Cells Dev.* 2008;17:725–36.
144. Neophytou CM, Trougakos IP, Erin N, Papageorgis P. Apoptosis deregulation and the development of cancer multi-drug resistance. *Cancers (Basel).* 2021;13:4363.
145. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. *Cancer Sci.* 2003;94:15–21.
146. Recasens A, Munoz L. Targeting cancer cell dormancy. *Trends Pharmacol Sci.* 2019;40:128–41.
147. Damen MPF, van Rheenen J, Scheele CLGJ. Targeting dormant tumor cells to prevent cancer recurrence. *FEBS J.* 288. John Wiley and Sons Inc; 2021. p. 6286–303.
148. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? *Nat Rev Cancer.* 2010;10:871–7.
149. Abderrahman B, Jordan VC. Rethinking extended adjuvant antiestrogen therapy to increase survivorship in breast cancer. *JAMA Oncol.* 2018;4:15.
150. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after

- diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet*. 2013;381:805–16.
151. Bonuccelli G, Peiris-Pages M, Ozsvari B, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. *Oncotarget*. 2017;8:9868–84.
 152. Bollard J, Miguela V, Ruiz de Galarreta M, Venkatesh A, Bian CB, Roberto MP, et al. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. *Gut*. 2017;66:1286–96.
 153. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. *J Cell Biol*. 1997;137.
 154. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). *Cancer Res*. 2003;63:1684–95.
 155. Brown JA, Yonekubo Y, Hanson N, Sastre-Perona A, Basin A, Rytlewski JA, et al. TGF- β -induced quiescence mediates chemoresistance of tumor-propagating cells in squamous cell carcinoma. *Cell Stem Cell*. 2017;21:650–664.e8.
 156. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. *Cell* 2012;150:764–79.
 157. Rammohan M, Harris E, Bhansali RS, Zhao E, Li LS, Crispino JD. The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target. *Oncogene*. 2022;41:2003–11.
 158. Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL, Zewe JP, et al. The DREAM complex mediates G1S1 cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis. *Cancer Res*. 2013;73:5120–9.
 159. Ewton DZ, Hu J, Vilenchik M, Deng X, Luk KC, Polonskaia A, et al. Inactivation of Mirk/Dyrk1b kinase targets quiescent pancreatic cancer cells. *Mol Cancer Ther*. 2011;10:2104–14.
 160. Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. *Genes Dev*. 2011;25:801–13.
 161. Rammohan M, Harris E, Bhansali RS, Zhao E, Li LS, Crispino JD. The chromosome 21 kinase DYRK1A: emerging roles in cancer biology and potential as a therapeutic target. *Oncogene*. 2022;41:2003–11.
 162. MacDonald J, Ramos-Valdes Y, Perampalam P, Litovchick L, DiMattia GE, Dick FA. A systematic analysis of negative growth control implicates the DREAM complex in cancer cell dormancy. *Mol Cancer Res*. 2017;15:371–81.
 163. Wang L, Leite de Oliveira R, Huijberts S, Bosdriesz E, Pencheva N, Brunen D, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. *Cell*. 2018;173:1413–25.e14.
 164. Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, et al. Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. *Nat Commun*. 2018;9:3815.
 165. Narasimha AM, Kaulich M, Shapiro GS, Choi YJ, Sicinski P, Dowdy SF. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation. *Elife*. 2014;3:e02872.
 166. Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA. ERK1/2 and p38 α / β signaling in tumor cell quiescence: opportunities to control dormant residual disease. *Clin Cancer Res*. 2011;17:5850–7.
 167. Martínez-Limón A, Joaquín M, Caballero M, Posas F, de Nadal E. The p38 pathway: from biology to cancer therapy. *Int J Mol Sci*. 2020;21:1913.
 168. Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. *Nat Rev Mol Cell Biol*. 2020;21:607–32.

AUTHOR CONTRIBUTIONS

ARB conceived the idea for the review. WAW wrote the manuscript. ARB revised and edited the manuscript.

FUNDING

WAW is funded by an MRC PhD studentship through core funding at the MRC-LMS (MC-A658-STY60). ARB is funded by a Cancer Research UK Career Development Fellowship (C63833/A25729).

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Alexis R. Barr.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023